These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
348 related articles for article (PubMed ID: 28674748)
1. Platelet-activating factor podoplanin: from discovery to drug development. Takemoto A; Miyata K; Fujita N Cancer Metastasis Rev; 2017 Jun; 36(2):225-234. PubMed ID: 28674748 [TBL] [Abstract][Full Text] [Related]
2. Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis. Sekiguchi T; Takemoto A; Takagi S; Takatori K; Sato S; Takami M; Fujita N Oncotarget; 2016 Jan; 7(4):3934-46. PubMed ID: 26684030 [TBL] [Abstract][Full Text] [Related]
3. Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents. Ukaji T; Takemoto A; Shibata H; Kakino M; Takagi S; Katayama R; Fujita N Cancer Sci; 2021 Jun; 112(6):2299-2313. PubMed ID: 33735501 [TBL] [Abstract][Full Text] [Related]
4. A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey ( Ukaji T; Takemoto A; Katayama R; Takeuchi K; Fujita N Oncotarget; 2018 Sep; 9(70):33322-33336. PubMed ID: 30279963 [TBL] [Abstract][Full Text] [Related]
5. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. Suzuki-Inoue K; Kato Y; Inoue O; Kaneko MK; Mishima K; Yatomi Y; Yamazaki Y; Narimatsu H; Ozaki Y J Biol Chem; 2007 Sep; 282(36):25993-6001. PubMed ID: 17616532 [TBL] [Abstract][Full Text] [Related]
6. Suppression of Aggrus/podoplanin-induced platelet aggregation and pulmonary metastasis by a single-chain antibody variable region fragment. Miyata K; Takagi S; Sato S; Morioka H; Shiba K; Minamisawa T; Takami M; Fujita N Cancer Med; 2014 Dec; 3(6):1595-604. PubMed ID: 25132683 [TBL] [Abstract][Full Text] [Related]
7. Functional characterization of recombinant snake venom rhodocytin: rhodocytin mutant blocks CLEC-2/podoplanin-dependent platelet aggregation and lung metastasis. Sasaki T; Shirai T; Tsukiji N; Otake S; Tamura S; Ichikawa J; Osada M; Satoh K; Ozaki Y; Suzuki-Inoue K J Thromb Haemost; 2018 May; 16(5):960-972. PubMed ID: 29488681 [TBL] [Abstract][Full Text] [Related]
8. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Kato Y; Kaneko MK; Kunita A; Ito H; Kameyama A; Ogasawara S; Matsuura N; Hasegawa Y; Suzuki-Inoue K; Inoue O; Ozaki Y; Narimatsu H Cancer Sci; 2008 Jan; 99(1):54-61. PubMed ID: 17944973 [TBL] [Abstract][Full Text] [Related]
9. The impact of Aggrus/podoplanin on platelet aggregation and tumour metastasis. Fujita N; Takagi S J Biochem; 2012 Nov; 152(5):407-13. PubMed ID: 22992842 [TBL] [Abstract][Full Text] [Related]
10. The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity. Kato Y; Kunita A; Abe S; Ogasawara S; Fujii Y; Oki H; Fukayama M; Nishioka Y; Kaneko MK Oncotarget; 2015 Nov; 6(34):36003-18. PubMed ID: 26416352 [TBL] [Abstract][Full Text] [Related]
11. Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. Takagi S; Sato S; Oh-hara T; Takami M; Koike S; Mishima Y; Hatake K; Fujita N PLoS One; 2013; 8(8):e73609. PubMed ID: 23991201 [TBL] [Abstract][Full Text] [Related]
12. C-type lectin-like receptor 2 promotes hematogenous tumor metastasis and prothrombotic state in tumor-bearing mice. Shirai T; Inoue O; Tamura S; Tsukiji N; Sasaki T; Endo H; Satoh K; Osada M; Sato-Uchida H; Fujii H; Ozaki Y; Suzuki-Inoue K J Thromb Haemost; 2017 Mar; 15(3):513-525. PubMed ID: 28028907 [TBL] [Abstract][Full Text] [Related]
13. Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies. Nakazawa Y; Takagi S; Sato S; Oh-hara T; Koike S; Takami M; Arai H; Fujita N Cancer Sci; 2011 Nov; 102(11):2051-7. PubMed ID: 21824222 [TBL] [Abstract][Full Text] [Related]
14. Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2. Ogasawara S; Kaneko MK; Price JE; Kato Y Hybridoma (Larchmt); 2008 Aug; 27(4):259-67. PubMed ID: 18707544 [TBL] [Abstract][Full Text] [Related]
15. [Identification of the novel platelet activation receptor CLEC-2 and Its pathological and physiological roles]. Suzuki Inoue K; Inoue O; Ozaki Y Rinsho Byori; 2010 Dec; 58(12):1193-202. PubMed ID: 21348239 [TBL] [Abstract][Full Text] [Related]
16. Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin. Suzuki-Inoue K Blood; 2019 Nov; 134(22):1912-1918. PubMed ID: 31778548 [TBL] [Abstract][Full Text] [Related]
18. Physiologic and pathophysiologic roles of interaction between C-type lectin-like receptor 2 and podoplanin: partners from in utero to adulthood. Suzuki-Inoue K; Osada M; Ozaki Y J Thromb Haemost; 2017 Feb; 15(2):219-229. PubMed ID: 27960039 [TBL] [Abstract][Full Text] [Related]